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osting by EAbstract Sepsis and its sequelae are still a major cause of morbidity and mortality in intensive care
units (ICU). The evidence that endogenous mediators actually mediate the individual’s response to
infection has led to various approaches to assess the individual’s contribution to the course of the
disease. The role of an individual’s genetic background and predisposition for the extent of inﬂam-
matory responses is determined by variability of genes encoding endogenous mediators that consti-
tute the pathways of inﬂammation. Pro- and anti-inﬂammatory responses contribute to the
susceptibility and outcome of patients with systemic inﬂammation and sepsis. Therefore, all genes
encoding proteins involved in the transduction of inﬂammatory processes are candidate genes to
determine the human genetic background that is responsible for interindividual differences in sys-
temic inﬂammatory responses. Polymorphism of TNA a, TNFB, IL-10, IL-6, IL-1b, IL-1RN,
HMGB1, TLR, PAI-1, DEFB1, HSP and MMP-9 has contribution to susceptibility and outcome
of sepsis in some research. Examination of the association between genetic polymorphisms and sep-
sis promises to provide clinicians with new tools to evaluate prognosis, to intervene early and
aggressively in treating high risk persons, and to avoid the use of therapies with adverse effects
in treating low risk persons. Genomic information may be useful to use to identify groups of
patients with a high risk of developing severe sepsis and multiple organ dysfunctions.
 2010 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.0850805; fax: +62 651 52053.
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Sepsis is a systemic inﬂammatory response syndrome arising
from infection. Severe sepsis is the sepsis associated with organ
dysfunction, hypoperfusion abnormality or sepsis-induced
hypotension [1]. Despite recent advances in antibiotic therapy,
aggressive operative intervention and intravenous hyperali-
mentation, sepsis, severe sepsis, and its sequelae are still re-
ported to contribute to signiﬁcant high morbidity and
mortality in the surgical intensive care unit. In various settings,
mortality rates of patients suffering from severe sepsis have
reached 20–70% [2]. Care of patients with sepsis costs as much
as $50,000 per patient, resulting in an economic impact of
nearly $17 billion annually in the United States [3]. Based on
these ﬁndings, it is essential to determine the mechanism
underlying the pathophysiology of sepsis in order to design
better intervention therapy.
Both pro and anti-inﬂammatory responses contribute to the
outcome of patients with systemic inﬂammation and sepsis.
Therefore, all genes encoding proteins involved in the trans-
duction of inﬂammatory processes are candidate genes to
determine the human genetic background responsible for inter-
individual differences in systemic inﬂammatory responses to
infection. This group of genes comprises, but is not restricted
to, cytokines and involves numerous other effector molecules
involved in inﬂammatory processes. Genes of the coagulation
system, heat shock proteins, or signal transduction molecules
contribute to the list of candidate genes for sepsis that show
genomic variation. Cytokines released from immunocompe-
tent cells are major players in the inﬂammatory response to
infection. Primary proinﬂammatory cytokines, such as tumor
necrosis factor alpha (TNFa) and interleukin-1 (IL-1), induce
secondary pro and anti-inﬂammatory mediators such as IL-6and IL-10 [4]. Genetic variation of this cytokines has been
shown to play a large role in determining susceptibility to
and outcome of sepsis.
This article will discuss the contribution of pro and anti-
inﬂammatory cytokine gene polymorphism to susceptibility
and outcome of patients with systemic inﬂammation and sepsis.2. Genes polymorphism and sepsis
2.1. Tumor necrosis factor (TNF) a
Odwyer et al. [5] examined the association of TNFa promoter
single nucleotide polymorphisms (SNP) and haplotypes with
gene expression in terms of mRNA levels and with outcome
in a cohort of patients with severe sepsis. There was a trend
for patients homozygous for the G allele at position 308 to
produce more TNFa mRNA on day 1 than those carrying
an A allele. Carrier status for haplotype 1 (with A at position
863 and G at position 308) was associated with greater
TNFa mRNA levels on day 1. Carrier status for haplotype 4
(with C at position 863 and A at position 308) was associ-
ated with a nonsigniﬁcant decrease in TNFa mRNA levels on
day 1. When directly compared, haplotype 1 was associated
with signiﬁcantly greater levels of TNFa mRNA than with
haplotype 4 on day 1. Patients homozygous for the A allele
at position 308 were more likely to succumb to severe sepsis
than those carrying the G allele.
These ﬁndings were supported by a previous study that
shown the Gﬁ A SNP at the 308 position in the TNFa pro-
moter increases the risk for severe sepsis after trauma [6], after
burn injury [7], in patients with community-acquired pneumo-
nia [8] and surgical infection [9].
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TNFb (lymphotoxin-a) is a cytokine that orchestrates lym-
phoid neogenesis and the formation of germinal center reac-
tions. In the ﬁrst intron of the TNFB, there is an Nco 1
polymorphism consisting of the allele TNFB1 in the presence
of the restriction site, and the allele TNFB2 in its absence.
Nco1 polymorphism was found to be correlated with an amino
acid variation of the TNFb sequence at position 26, which is
asparagine for the TNFB1 sequence and threonine for the
TNFB2 sequence. With regard to the functional consequences
of TNF synthesis, it was found that phytohemagglutinin-stim-
ulated peripheral blood mononuclear cells from TNFB1-
homozygous individuals showed a signiﬁcantly increased
TNFb production, whereas phytohemagglutinin- and endo-
toxin-stimulated monocytes from TNFB2-homozygous indi-
viduals showed a signiﬁcantly higher production of IL-1b
and TNFa [10].
A study conducted by Majetschak et al. [11] had shown that
genotypes were related to the occurrence of severe posttrau-
matic sepsis and TNFa serum concentrations. Genotype distri-
bution in patients with an uncomplicated clinical course was
signiﬁcantly different from that in patients with severe post-
traumatic sepsis. Development of severe posttraumatic sepsis
was signiﬁcantly increased in patients homozygous for the al-
lele TNFB2. In patients with severe posttraumatic sepsis,
TNFa serum concentrations were signiﬁcantly higher in
TNFB2-homozygous individuals compared with heterozygous
and TNFB1-homozygous individuals. Thus in multiply injured
patients, the Nco1 polymorphism within the TNFb gene is
associated with the development of severe posttraumatic sepsis
and with increased TNFa serum levels when severe sepsis has
occurred.2.3. Tumor necrosis factor receptor (TNFR)
In the case of TNF, regulatory mechanisms include shedding
into the circulation of two membrane-bound TNF receptors,
TNFRSF1A (TNFR1) and TNFRSF1B (TNFR2). Cleavage
of the extracellular portion of these receptors produces soluble
molecules (sTNFRSF1Aand sTNFRSF1B) in the blood that re-
tain the ability to bind TNF and inhibit its acute activity. Evi-
dence is gradually emerging that genetic variations within the
TNF receptor gene loci may be important in the pathogenesis
of various inﬂammatory conditions. Polymorphisms within
the TNFRSF1B locus have also been associated with other con-
ditions in which TNF is believed to play an important role [12].
A study [13] conducted to investigate whether common
polymorphisms of the TNF locus and the two receptor genes,
TNFRSF1A and TNFRSF1B, associated with susceptibility,
severity of illness or outcome in adult patients with severe sep-
sis or septic shock reported that in patients with severe sepsis
and septic shock, plasma levels of TNF and its two soluble
receptors, sTNFRSF1A and sTNFRSF1B, were higher in
nonsurvivors than in survivors.2.4. Interleukin-10
IL-10 is the most potent anti-inﬂammatory cytokine, as it
downregulates the production of proinﬂammatory cytokinesand chemokines secreted by activated monocytes, polymor-
phonuclear leucocytes and eosinophils, prevents antigen-
speciﬁc T-cell activation, inhibits T-cell expansion, and poten-
tiates the release of the inﬂammatory modulator IL-1ra. IL-10
may play a role in the pathogenesis of severe sepsis.
An anti-inﬂammatory cytokine proﬁle of high IL-10 pro-
duction has been observed to correlate with the development
of meningococcal disease and community-acquired infection
[14], while genomic polymorphisms within the IL-10 gene have
been demonstrated as being associated with inter-individual
differences in IL-10 production [15]. The plasma concentration
of IL-10 in patients with sepsis has been shown to be correlated
with both the severity and the outcome of sepsis [16,17].
Qiang et al. [18] conducted a study in China to investigate
whether three biallelic polymorphisms at positions 592,
819 and 1082 in the promoter region of the IL-10 gene
are associated with increased incidence of severe sepsis. They
found that patients with severe sepsis were more likely to have
IL-10 1082 allele 1, compared with controls. Genotype distri-
bution of the IL-10 1082 polymorphism signiﬁcantly differed
between patients and controls. However, the allele frequencies
and genotype distribution of the IL-10 1082 polymorphism
did not differ between surviving and dead patients. No signif-
icant differences in the genotype distribution and allele fre-
quencies of the IL-10 592 and IL-10 819 polymorphisms
were observed between patients with severe sepsis and healthy
controls, or between surviving and dead patients.
The other study [19] analyzed 284 adult patients presenting
to the Emergency Department (ED) with community-acquired
pneumonia (CAP). Subjects with either genotype C/T or T/T
at IL-10 819 were associated with a greater risk of progres-
sion to severe sepsis compared with the common homozygote
C/C. This study did not ﬁnd a consistent difference in plasma
IL-10 levels between subjects with different genotypes. In this
preliminary analysis of subjects with CAP, those with the IL-
10 819 C/T or T/T genotypes are more likely to develop se-
vere sepsis compared with those with the usual homozygous C/
C phenotype.2.5. Interleukin-6
IL-6 is a pleiotropic cytokine expressed in many tissues. A poly-
morphism in the IL-6 gene, associated with differences in the
IL-6 transcription rate, has been described. A biallelic polymor-
phismwithin the human IL-6 gene promoter region (174G/C)
has been shown to affect IL-6 transcription in vitro and IL-6
plasma levels in healthy adults. IL-6 is excessively released into
the circulation during sepsis and closely correlates with the clin-
ical course. Schluter et al. [20] studied whether this promoter
polymorphism has an effect on the incidence and/or outcome
of sepsis in surgical ICU in a German university hospital. They
found study ﬁnd that genotype distribution and allele frequen-
cies did not differ signiﬁcantly between patients with or without
sepsis andhealthy controls. In patientswhoﬁnally succumbed to
sepsis, signiﬁcantly less GG homozygotes were observed com-
pared with survivors. Median systemic IL-6 levels in septic pa-
tients closely correlated with outcome but were not associated
with the IL-6 promoter genotype. The IL-6 promoter polymor-
phism (174 G/C) does not affect the incidence of sepsis. How-
ever, the GG homozygous genotype is signiﬁcantly associated
with an improved survival in sepsis.
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IL-6 gene promoter 174 G/C on the severity of systemic
inﬂammatory response syndrome (SIRS) associated with
CAP was studied by Martı´n-Loeches et al. [21]. This research
showed that the distribution of the G/C 174 genotype was
similar in CAP patients and controls. In patients who were
admitted with CAP, no signiﬁcant differences were observed
compared with progression between groups. These ﬁndings
demonstrate that the 174G/C polymorphism is not associated
with risk and outcome of CAP in the Spanish white Caucasian
population.
2.6. Interleukin 1b
IL-1b is a potent proinﬂammatory cytokine released by macro-
phages involved in the systemic inﬂammatory response. IL-1b
is capable of inducing the symptoms of septic shock and organ
failure in animal models and is regarded as a primary mediator
of the SIRS [22]. Despite the ﬁnding that a homozygous TaqI
genotype correlates with high secretion of IL-1b, genotyping of
patients with severe sepsis did not reveal any association with
incidence or outcome of the disease [23].2.7. Interleukin-1 receptor antagonist gene (IL-1RN)
The polymorphic region within intron 2 of the IL-1RN* gene
contains a variable numbers of tandem repeats (VNTR) of
86 bp, ﬁve alleles of the IL-1RN* have been reported
(*1–*5), corresponding to 2, 3, 4, 5 and 6 copies of the 86-bp
sequence, respectively [24]. Ex vivo experiments suggested
greater IL-1ra responses associated with alleles containing
small numbers of the 86-bp repeat. Ex vivo studies also demon-
strated higher levels of IL-1ra protein expression and protein
release for A2 homozygous individuals, compared with hetero-
zygotes, after stimulation with LPS [25]. There previous study
shown that the allele frequency of the allele IL-1raA2 was in-
creased in 93 patients with severe sepsis compared with normal
individuals (p< .01) but no association with patients’ out-
come was observed [26].
The research that conducted by Arnalich et al. [24], found
that compared with patients homozygous or heterozygous for
the allele *1, IL-1RN*2 homozygotes produced signiﬁcantly
lower levels of IL-1Ra from patient PBMC. This result pro-
vides evidence that homozygosity of the IL-1RN*2 is associ-
ated with a decreased production of IL-1Ra in PBMC and
higher mortality risk during severe sepsis. These ﬁndings
are consistent with the hypothesis that individuals producing
lower amounts of IL-1Ra are afforded a lower level of pro-
tection against fatal outcome than subjects producing higher
levels.
2.8. High mobility group box 1 protein (HMGB1)
HMGB1 is a pleiotropic cytokine, recently implicated in the
pathophysiology of the SIRS and sepsis. HMGB-1 is a fascinat-
ing andmarkedly complex nuclear and cytoplasmic protein that
is readily measurable in the systemic circulation in response to
severe injury. The protein has the propensity to bind to a variety
of inﬂammatory mediators such as lipopolysaccharide and pro-
inﬂammatory cytokines, including IL-1 [27]. HMGB-1 func-
tions as an alarmin or damage-associated molecular patternmolecule, and acts as an endogenous ligand for pattern recogni-
tion receptors of the innate immune system [28].
Kornblit et al. [29] reported the ﬁrst evidence of the
HMGB-1 genotype’s impact on the risk of SIRS and sepsis.
These investigators performed a long-term, 4-year study com-
paring HMGB-1 sequencing data in 239 ICU patients with
HMGB-1 blood levels and clinical outcomes. A promoter var-
iant (1377delA) was associated with a markedly reduced
long-term survival rate after ICU admission in SIRS patients.
They also observed a signiﬁcant interaction with a polymor-
phism within the coding region of the HMGB-1 gene at posi-
tion 982 (C > T) in exon 4. Carriers of the polymorphism
had an increased frequency of early death from infection along
with higher Simpliﬁed Acute Physiology Score II compared
with wild-type genotypes. Interestingly, this 982C > T variant
was accompanied by signiﬁcantly lower HMGB-1 blood levels.
2.9. Toll like receptors (TLR)
More than half of the cases of sepsis are caused by gram-
negative bacteria. Because TLR4 is required for innate
immune responses to LPS, several research have investigated
possible associations between the Asp299Gly polymorphism
and sepsis [30]. Two of these studies demonstrated that this
polymorphism increases the risk of gram negative infections
[31,32], and another study linked this polymorphism to an in-
creased incidence of SIRS [33]. However, it is likely that the
impact of the Asp299Gly polymorphism on sepsis is restricted
to gram negative infections, because the Asp299Gly polymor-
phism does not affect polymicrobial sepsis [34].
With regard to other pathogens, an association between the
Asp299Gly polymorphism of TLR4 and severe respiratory
syncytial virus-induced bronchiolitis was reported. Respiratory
syncytial virus is a known ligand for TLR4. Taken together,
these data suggest that human TLR4 has a critical role in
the innate immune response to gram negative bacteria and
respiratory syncytial virus, although the cellular and molecular
events affected by the TLR4 polymorphisms in pathogen-
esis and adaptive responses to infection have not yet been
identiﬁed.
2.10. Plasminogen activator inhibitor type 1 (PAI-1)
Plasminogen activator inhibitor type 1 (PAI-1) is a 50 kilodal-
ton glycoprotein of the serine protease inhibitor family. The
primary role of PAI-1 in vivo is the inhibition of both tissue
and urokinase type plasminogen activators. In addition to this
function, PAI-1 acts as an acute phase protein during acute
inﬂammation. PAI-1 is a pivotal player in the pathogenesis
of sepsis. In patients with sepsis, the levels of PAI-1 are posi-
tively related to poor outcome, increased severity of disease,
and increased levels of various cytokines, acute phase proteins,
and coagulation parameters.
Kornelisse et al. [35] have investigated the relation between
PAI-1 and TNF-a, which is the principal stimulator, and have
found a difference between survivors and nonsurvivors: the
production of PAI-1 in nonsurvivors was 1.9 times higher for
the same levels of TNFa. Hermans et al. [36] found that patients
with the 4G/4G genotype had signiﬁcantly higher PAI-1 con-
centrations than did those with the 4G/5G or 5G/5G genotype.
Haralambous et al. [37] have recently conﬁrmed in an indepen-
dent study that white pediatric patients carrying the functional
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vascular complications and dying from meningococcal disease.
The 4G/5G insertion/deletion promoter polymorphism, which
leads to differences in PAI-1 production, has been demon-
strated to affect the risk of developing severe complications
and dying from sepsis during meningococcal infection and
multiple traumas [38]. Menges et al. [39] demonstrated that
the genetic predisposition to produce high levels of PAI-1 (the
4G/4G genotype) is associated with poor prognosis and out-
come of severe trauma. The PAI-1 4G allele is associated with
high PAI-1 plasma concentrations and a poor survival rate in
these patients.
2.11. Human b-defensin 1 (DEFB1)
DEFB1 is a multifunctional mediator in infection and inﬂam-
mation, which has been largely explored in ex vivo studies.
Fang et al. [40] conducted a research to investigate whether
DEFB1 genomic variations are associated with incidence
and outcome of severe sepsis. Six reported polymorphisms
were detected. The 44G-allele and 44G-allele carrying
genotypes were signiﬁcantly associated with the incidence
and outcome of severe sepsis. The 20G allele and GG geno-
type were associated with susceptibility to severe sepsis, while
the 1816G-allele and 1816G-allele carrying genotypes
inﬂuenced the outcome of severe sepsis. Haplotype 20A/
44C/52G showed a protective role against severe sepsis,
whereas haplotype 20G/44G/52G served as a risk factor
for fatal outcome of severe sepsis. The present ﬁndings have
important implications in the understanding of the role of
DEFB1 in the pathophysiology of severe sepsis, and DEFB1
genomic variations may offer a new means of risk stratiﬁca-
tion for patients with severe sepsis.
2.12. Heat shock protein (HSP)
HSPs are expressed in response to heat shock and a variety
of other stimuli, including endotoxin and other mediators of
severe sepsis. Three genes encoding members of the HSP
family lie in the class III region of the MHC. Individuals
carrying the polymorphism HSP70-2G exhibit lower levels
of mRNA ex-vivo. Schroeder et al. [41] hypothesized that
individuals homozygous for the HSP70-2G allele should
have greater susceptibility to and/or higher mortality from
sepsis compared to other genotypes. They tested this hypoth-
esis in 87 patients admitted to a surgical ICU with severe
sepsis and found no association. They did ﬁnd a linkage be-
tween HSP70-2A (the ‘‘protective’’ allele) and TNF-b2, an
allelic variant previously shown to be associated with higher
TNF-a levels and worse outcome from sepsis. The overall
mortality in the group of HSP-2G homozygotes was not
increased possibly because of linkage with the non-TNF-b2
haplotype. This ﬁnding highlights the importance of
knowing all the polymorphisms relevant to the inﬂammatory
response in individuals rather than interpreting a polymor-
phism in isolation.
2.13. Matrix metalloproteinase-9 (MMP-9)
MMP-9 is involved in extracellular matrix degradation and
leukocyte migration. MMP-9 has been demonstrated to playan important role in organ dysfunction and outcome of sepsis
in mouse [42]. This research found that using E. coli peritonitis,
MMP-9/ mice (MMP-9 gene-deﬁcient) showed much higher
peritoneal chemokine and cytokine levels compared with wild-
type mice beside that MMP-9/ mice displayed a diminished
recruitment of leukocytes to the site of infection, indicating
that cellular migration was impaired. Moreover, MMP-9/
mice developed more severe distant organ damage during
infection. However, genetic predisposition of MMP-9 to sepsis
remained unknown.
Seven common SNPs within the functional regions of
MMP-9 gene (rs17576, rs2274756, rs2250889, rs9509,
rs3918240, rs3918241 and rs3918242) have investigated in
human. Research that conducted by Chen [43] showed that
the genotype distributions and allelic frequencies of the above
seven SNPs were not signiﬁcantly different between patients
with severe sepsis and controls, as well as between surviving
and nonsurviving patients with severe sepsis. Haplotype
GGCTTTC, AGGTCTC, GGCCTTC, GACTTAT and
AGCCCTC are the ﬁve most common haplotypes. The distri-
bution of the haplotypes was also comparable among the de-
ﬁned groups. The median plasma levels of MMP-9 was
37.66 ng/ml in 32 patients within the ﬁrst 24 h following the
diagnosis of severe sepsis, and 30.15 ng/ml in 19 healthy con-
trols. Compared with those in surviving patients with severe
sepsis and healthy controls, the concentrations of MMP-9 ap-
peared an increasing trend in nonsurviving patients with severe
sepsis. This ﬁnding suggest that common polymorphisms with-
in the function regions of MMP-9 gene may not play a major
role in the predisposition to severe sepsis in the Chinese Han
cohort but the plasma levels of MMP-9 may associate with
the outcome of severe sepsis.3. Conclusions
Polymorphisms of many inﬂammatory cytokine gene, innate
immunity pathway gene, and coagulation cascade polymor-
phisms has been shown to play a large role in determining sus-
ceptibility to and outcome of such complex diseases as sepsis.
Examination of the association between genetic polymorphisms
and sepsis promises to provide clinicians with new tools to eval-
uate prognosis, to intervene early and aggressively in treating
high risk persons, and to avoid the use of therapies with adverse
effects in treating low risk persons.3.1. Key messages
Conﬁrmation in large, well conducted, multicenter studies
is required to conﬁrm current ﬁndings and to make them
clinically applicable. Unbiased investigation of all genes in
the human genome is an emerging approach. New, eco-
nomical, high-throughput technologies may make this pos-
sible [44].
High-throughput techniques, such as genome-wide scans,
will allow genotyping of a large number of SNP throughout
the human genome. There is intense interest to apply this tech-
nology to understand genetics of severe sepsis. By performing
genome-wide association studies, genome-wide scans of
nonsynonymous SNP, and testing for differential allelic
expression and copy number polymorphisms, we may yet be
102 H. Tumangger, K.F. Jamilable to tease out the complex inﬂuence of genetic variation on
susceptibility and response to sepsis.4. Disclosure statement
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